Market Place
Sourcing Support
Evaxion provides update on MSD collab For Gonorrhea EVX-B2
20 Dec 2025 //
FIERCE BIOTECH
FDA Grants Priority Vouchers to Merck`s Drugs
20 Dec 2025 //
REUTERS
Merck Expands Medicine Access, Lowers Costs For Americans
19 Dec 2025 //
BUSINESSWIRE
Adagene Reveals FDA Fast Track For Muzastotug In Cancer
16 Dec 2025 //
GLOBENEWSWIRE
Merck Get Positive EU CHMP Opinion for Expanded Use of Winrevair
12 Dec 2025 //
PHARMIWEB
FDA Launches Probe Into Safety Of Approved Anti-RSV Antibodies
10 Dec 2025 //
BIOSPACE
Merck, Sanofi, AZ Shots For RSV Now Under Scrutiny By FDA
09 Dec 2025 //
FIERCE PHARMA
BenchSci, Merck Extend ASCEND for Disease Biology
09 Dec 2025 //
PHARMIWEB
Merck mulls PV program’s future while Takeda takes victory lap
08 Dec 2025 //
FIERCE BIOTECH
Merck`s Keytruda SC Launch In Germany Faces Legal Hurdle
05 Dec 2025 //
FIERCE PHARMA
Merck Announces Winners Of The Merck Young Scientist Award 2025
03 Dec 2025 //
EXPRESSPHARMA
Merck Unveils Alzheimer`s Data on MK-2214, MK-1167 at CTAD 2025
01 Dec 2025 //
PHARMIWEB
Merck Joins Citi 2025 Global Healthcare Conference
26 Nov 2025 //
BUSINESSWIRE
Merck Joins 8Th Evercore ISI Healthconx Conference
26 Nov 2025 //
BUSINESSWIRE
Kelun-Biotech Initiates Phase III Trial For SAC-TMT with Keytruda
24 Nov 2025 //
PR NEWSWIRE
Merck To Present Hematology Pipeline Advancements At ASH 2025
24 Nov 2025 //
BUSINESSWIRE
FDA Approves Combo Therapy For Ineligible Bladder Cancer Patients
23 Nov 2025 //
INDPHARMAPOST
Merck`s WINREVAIR Promising In Phase 2 Study For Pulmonary
21 Nov 2025 //
INDPHARMAPOST
Merck Recommends Rejection Of Tutanota`s `Mini-Tender` Offer
21 Nov 2025 //
BUSINESSWIRE
EU Approves Subcutaneous Keytruda for All Adult Indications
19 Nov 2025 //
BUSINESSWIRE
Merck`s HIV Combo Matches Gilead`s Biktarvy In Phase 3 Test
19 Nov 2025 //
BUSINESSWIRE
Merck Boosts Winrevair`s Success In Mid-Stage Hypertension Data
19 Nov 2025 //
BUSINESSWIRE
Merck Boosts Winrevair`s Success In Mid-Stage Hypertension Data
18 Nov 2025 //
BUSINESSWIRE
Merck Announces First-Quarter 2026 Dividend
18 Nov 2025 //
BUSINESSWIRE
Solve Therapeutics Secures $120M For Leading ADCs In Solid Tumor
17 Nov 2025 //
BUSINESSWIRE
Merck to Acquire Cidara Therapeutics
14 Nov 2025 //
BUSINESSWIRE
Merck Joins Jefferies Global Healthcare Conference In London
13 Nov 2025 //
BUSINESSWIRE
Merck`s Enlicitide Decanoate Reduces LDL-C In HeFH Adults
09 Nov 2025 //
BUSINESSWIRE
Merck Enlicitide Decanoate Lowers LDL-C In Ph3 CORALreef Trial
08 Nov 2025 //
BUSINESSWIRE
MSD secures $700M Boost from Blackstone to ADC therapy
07 Nov 2025 //
BUSINESSWIRE
Merck Foundation Pumps $22M Into Heart Health Equity Programs
07 Nov 2025 //
FIERCE PHARMA
Merck Signs Agreement with Dr. Falk Pharma GmbH for MK-8690
04 Nov 2025 //
PRESS RELEASE
Merck Foundation Launches $22M to Improve Cardiovascular Care
03 Nov 2025 //
BUSINESS WIRE
Merck Reveals Q3 2025 Financial Results
30 Oct 2025 //
BUSINESSWIRE
Merck`s Pneumococcal Shot Capvaxive Off To `Very Strong Start`
30 Oct 2025 //
FIERCE PHARMA
EC Approves Keytruda Combo for PD-L1+Resectable Head&Neck Cancer
29 Oct 2025 //
BUSINESSWIRE
Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer
29 Oct 2025 //
FIERCE PHARMA
Welireg`s RCC Wins Could Pad Merck`s Post-Keytruda Sales
28 Oct 2025 //
FIERCE PHARMA
Merck Nabs updated FDA label for PAH med Winrevair
27 Oct 2025 //
BUSINESSWIRE
FDA Prioritizes KEYTRUDA And KEYTRUDA QLEX Combo with Padcev
23 Oct 2025 //
BUSINESSWIRE
Merck To Unveil Cardio-Pulmonary Pipeline Data At AHA Conference
23 Oct 2025 //
BUSINESSWIRE
Keytruda, Lenvima Show Long-Term Survival Benefit in Cancer
22 Oct 2025 //
INDPHARMAPOST
KEYTRUDA® Shows Prolonged Survival Benefit In Some NSCLC Patients
20 Oct 2025 //
BUSINESSWIRE
Immunos Therapeutics Shows IOS-1002 Promise In Advanced Solid
20 Oct 2025 //
PHARMIWEB
Merck Grows More Ambitious About `Workhorse` TROP2 ADC
20 Oct 2025 //
FIERCE PHARMA
Merck Grows Again In Va. With $3B Small-Molecule Drug Plant
20 Oct 2025 //
FIERCE PHARMA
ESMO: Daiichi, Merck Move Ovarian Cancer ADC Toward Pivotal Test
20 Oct 2025 //
FIERCE BIOTECH
AZ Faces FDA Challenge As Imfinzi-Lynparza Miss Survival Goal
19 Oct 2025 //
FIERCE PHARMA
Keytruda and Lenvima Show Long-Term Survival Benefit
18 Oct 2025 //
BUSINESSWIRE
Keytruda, Padcev Cut Risk Of Death By 50% In MIBC Patient Subset
18 Oct 2025 //
FIERCE PHARMA
Merck`s KEYNOTE-B96 Phase 3 Trial Meets Secondary Endpoint
16 Oct 2025 //
BUSINESSWIRE
In Ovarian Cancer, Keytruda Follows PFS Win With Survival Showing
16 Oct 2025 //
FIERCE PHARMA
Merck Reports Ph3 HIV Data for Oral DOR/ISL Combination Drug
15 Oct 2025 //
PHARMIWEB
Moderna Claims Early Victory For Cancer Antigen In Melanoma
13 Oct 2025 //
BIOSPACE
Merck Expands Keytruda`s Role In Cancer Innovation To New Tumor
11 Oct 2025 //
INDPHARMAPOST
Merck To Unveil HIV Pipeline Data At European AIDS Conf 2025
09 Oct 2025 //
PHARMIWEB
Merck Advances Oncology Innovation At ESMO 2025
09 Oct 2025 //
PHARMIWEB
Immutep Shares Update on Ph3 TACTI-004 Trial in Lung Cancer
09 Oct 2025 //
GLOBENEWSWIRE
Bioinvent Starts BI-1206 Ph 2a Trial In Advanced NSCLC & Melanoma
08 Oct 2025 //
PR NEWSWIRE
Merck Completes Acquisition Of Verona Pharma
07 Oct 2025 //
PRESS RELEASE
